What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?

Amir M Mohareb; Menan Gérard Kouamé; Marcellin Nouaman; Arthur Y Kim; Joseph Larmarange; Anne M Neilan; Karine Lacombe; Kenneth A Freedberg; Anders Boyd; Patrick Coffie

doi:10.1002/jia2.26218

What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?

Identifier:nobleid.org/w1/20260515/09C25ADF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/09C25ADF.svg?ark=w1%2F20260515%2F09C25ADF)](https://nobleid.org/work/w1/20260515/09C25ADF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?

Identifier:nobleid.org/w1/20260515/09C25ADF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/09C25ADF.svg?ark=w1%2F20260515%2F09C25ADF)](https://nobleid.org/work/w1/20260515/09C25ADF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work